LLY vs. UTHR: Eli Lilly vs. United Therapeutics Stock Comparison

November 11, 2026

How do Eli Lilly (LLY) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but LLY is classified in Pharmaceuticals while UTHR is classified in Biotechnology.

Company profile comparison for Eli Lilly (LLY) and United Therapeutics (UTHR)
Profile Item	LLY	UTHR
Name	Eli Lilly and Company	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Biotechnology
GICS Sub-Industry	Pharmaceuticals	Biotechnology
Market Capitalization	1,206.07 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 1, 1972	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

LLY

UTHR

GSPC

Eli Lilly (LLY) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
Total Return (1Y)	52.36%	28.77%
Total Return (3Y, Annualized)	34.18%	37.63%
Total Return (5Y, Annualized)	41.08%	23.78%

Risk Profile

Drawdown History

LLY

UTHR

GSPC

Eli Lilly (LLY) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
Volatility (1Y, Annualized)	35.34%	35.00%
Beta (5Y)	0.40	0.49
Max Drawdown (5Y)	-34.48%	-33.00%
Avg. Volume (3M)	2.52M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

LLY and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
Sharpe Ratio (1Y)	1.36	0.70
Sortino Ratio (1Y)	2.29	1.29

Profitability

ROE (TTM)

Both Eli Lilly (LLY) at 86.02% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Eli Lilly (LLY) at 31.90% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Eli Lilly (LLY) at 53.66% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
ROE (TTM)	86.02%	19.13%
ROA (TTM)	21.06%	10.91%
Net Margin (TTM)	31.90%	38.61%
Operating Margin (TTM)	53.66%	28.99%
Gross Margin (TTM)	83.63%	86.34%

Growth

Revenue Growth

Both Eli Lilly (LLY) at 44.70% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while United Therapeutics (UTHR) at 13.07% is closer to the peer norm — faster per-share earnings growth for LLY.

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
Revenue Growth (YoY)	44.70%	10.61%
Revenue Growth (3Y CAGR)	31.69%	18.02%
EPS Growth (YoY)	95.99%	13.07%
EPS Growth (3Y CAGR)	51.71%	22.92%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Eli Lilly (LLY) carries debt-to-equity ratio of 1.23 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Eli Lilly (LLY) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
Current Ratio (MRQ)	1.39	4.61
Debt / Equity (MRQ)	1.23	--
Net Debt / EBITDA	0.96	-1.53

Dividends

Dividend Yield (TTM)

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

United Therapeutics (UTHR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
Dividend Yield (TTM)	0.49%	0.00%
Dividend Payout Ratio (TTM)	21.71%	0.00%

Valuation

P/E Ratio (TTM)

United Therapeutics (UTHR) at 21.22 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Eli Lilly (LLY) at 13.95 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Eli Lilly (LLY) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and United Therapeutics (UTHR)
Metric	LLY	UTHR
P/E Ratio (TTM)	43.95	21.22
P/S Ratio (TTM)	13.95	7.51
P/B Ratio (MRQ)	29.96	3.80
Free Cash Flow Yield (TTM)	0.77%	1.90%